• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, ASHITAKA CAPIOX FX25 OXYGENATOR; OXYGENATOR, CARDIOPULMONARY BYPASS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, ASHITAKA CAPIOX FX25 OXYGENATOR; OXYGENATOR, CARDIOPULMONARY BYPASS Back to Search Results
Catalog Number CX-FX25E
Device Problem Increase in Pressure (1491)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 08/11/2022
Event Type  malfunction  
Event Description
The user facility reported that due to the pre oxygenator pressure increase to 450mmhg (flow rate 2l/min) of the capiox custom pack, preparations were made to replace the oxygenator.After, the pressure dropped to 250 mmhg (flow rate: 4.8 l/min).The device was replaced with an oxygenator unit fx25e.As a result, the pre oxygenator pressure became 300 mmhg at a flow rate of 4.8 l/min, which was higher than before the replacement.Afterwards, the pre oxygenator pressure did not decrease; however, the device was used until the end of pumping.There was no patient injury/medical or surgical intervention required.The procedure outcome was not reported.The final patient impact was not harmed.The event occurred intra-operative.
 
Manufacturer Narrative
Implanted date: device was not implanted.Explanted date: device was not explanted.Health professional: requested, unknown occupation - clinical engineer.Pma/510(k) - k130280.Visual inspection of the actual sample did not find any anomaly such as a breakage in its appearance.After the saline solution was flowed into the actual sample by a head, visual inspection of the gas transfer section was performed.As a result, the formation of blood clot was found; however, it was not possible to clarify the timing of the formation of this blood clot (e.G., at the time of use, or at the time of return).After the investigation, the actual sample was installed into a circuit consisting of tubes, and the pressure drop when circulating saline solution in the blood channel at each flow rate was measured.No significant difference was found compared to the current product.After filling the saline solution containing glutaraldehyde solution in the actual sample and fixing the blood clot found, the housing and filter were removed, and visual inspection of the gas transfer section was performed.No blood clot formation leading to increased pressure was found.No anomaly was found in the winding state of the fiber.After investigation of the actual sample, the fiber layer was removed, and visual inspection of the gas transfer section was performed.No blood clot formation leading to increased pressure was found.No anomaly was found in the winding state of the fiber.The outer cylinder was removed from the actual heat exchanger, and visual and magnifying inspections of the heat exchanger was performed.As a result, the formation of blood clot was found on the bottom surface.No anomaly such as a deformation of oxygenator that led to an obstruction was found.Electron microscopic inspection of the actual fiber found that blood cell components such as white blood cells and blood platelets had been adhered.Review of the manufacturing history record and the shipping inspection record of the actual sample confirmed that there were not any indications of anomaly in them.A search of the complaint file found no other similar report with the involved product code/lot number combination.Based on the investigation result, the pressure drop of the actual sample upon receipt was the same as the current product, and no obstruction was found.Although blood cell components such as blood platelets and white blood cells adhered to the fiber of actual sample, no blood clot formation leading to an increase in pressure was found.Therefore, it was not possible to clarify the cause of occurrence.Relevant ifu reference: "do not reduce heparin during circulation.Otherwise, blood clotting might occur.(warnings)" "adequate heparinization of the blood is required to prevent it from clotting in the system.(warnings)" (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CAPIOX FX25 OXYGENATOR
Type of Device
OXYGENATOR, CARDIOPULMONARY BYPASS
Manufacturer (Section D)
TERUMO CORPORATION, ASHITAKA
150 maimaigi-cho
fujinomiya city, 418
JA  418
Manufacturer (Section G)
TERUMO CORPORATION, ASHITAKA
reg. no. 9681834
150 maimaigi-cho
fujinomiya city, 418
JA   418
Manufacturer Contact
gina digioia
reg. no. 2243441
950 elkton blvd.
elkton, MD 21921
6402040886
MDR Report Key15380908
MDR Text Key306268182
Report Number9681834-2022-00175
Device Sequence Number1
Product Code DTZ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K071572
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility,Company Representative
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 09/08/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue NumberCX-FX25E
Device Lot Number220310
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer08/17/2022
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/12/2022
Initial Date FDA Received09/08/2022
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured03/10/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-